Literature DB >> 23263594

Interdisciplinary treatment of unruptured intracranial aneurysms: impact of intraprocedural rupture and ischemia in 563 aneurysms.

Mathias Kunz1, Yasmin Bakhshai, Stefan Zausinger, Gunther Fesl, Hendrik Janssen, Hartmut Brückmann, Jörg Christian Tonn, Christian Schichor.   

Abstract

This study was conducted to determine the risk factors and the clinical impact of intraprocedural aneurysm rupture (IAR) and periprocedural ischemia in the treatment of symptomatic and asymptomatic unruptured intracranial aneurysms (UIAs). A single-center retrospective data analysis of 563 UIAs treated between 2000 and 2010 was conducted. Treatment assignment was made on the basis of individual aneurysmal criteria in an interdisciplinary neurovascular conference with attending neurosurgeons, neuroradiologists and neurologists. In 363 microsurgical and 200 endovascular procedures, the permanent morbidity rate was 4.9 and 6 %. The overall mortality rate was 0.7 %-no procedure-related death occurred in microsurgery, and four patients had fatal outcomes after endovascular treatment. IAR occurred in 34 (9.4 %) microsurgical and 8 (4 %) endovascular procedures (p = 0.03). Risk factors for IAR were age, aneurysm diameter, symptomatic aneurysms, hypertension and smoking in microsurgery. IAR was associated with significantly worse outcome at discharge after microsurgical and at discharge and follow-up after endovascular procedures and was followed by fatal outcome in four endovascular cases. Periprocedural ischemia (12.1 vs. 9 %) resulted in significantly worse outcome in both groups. Risk factors for periprocedural ischemia were IAR during microsurgery, aneurysm diameter, symptomatic aneurysms and smoking in either group. Treatment of UIAs can be conducted with an equivalent low rate of permanent morbidity for clipping and coiling-treatment of symptomatic aneurysms elevates the procedural risk. IAR was less frequent during coiling, but was associated with relevant mortality. IAR and periprocedural ischemia represent significant treatment-associated risks, which should be taken into account in interdisciplinary treatment planning and patient counseling.

Entities:  

Mesh:

Year:  2012        PMID: 23263594     DOI: 10.1007/s00415-012-6795-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

1.  Recommendations for the management of patients with unruptured intracranial aneurysms: A Statement for healthcare professionals from the Stroke Council of the American Heart Association.

Authors:  J B Bederson; I A Awad; D O Wiebers; D Piepgras; E C Haley; T Brott; G Hademenos; D Chyatte; R Rosenwasser; C Caroselli
Journal:  Stroke       Date:  2000-11       Impact factor: 7.914

Review 2.  [Recommendations for the management of unruptured intracranial aneurysms].

Authors:  A Raabe; V Seifert; P Schmiedek; H Steinmetz; H Bertalanffy; H-J Steiger; D Stolke; M Forsting
Journal:  Zentralbl Neurochir       Date:  2002

3.  Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention.

Authors: 
Journal:  N Engl J Med       Date:  1998-12-10       Impact factor: 91.245

4.  Multicenter trial of hemodilution in ischemic stroke--background and study protocol. Scandinavian Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1985 Sep-Oct       Impact factor: 7.914

5.  Cerecyte coil trial: procedural safety and clinical outcomes in patients with ruptured and unruptured intracranial aneurysms.

Authors:  S Coley; M Sneade; A Clarke; Z Mehta; D Kallmes; S Cekirge; I Saatci; D Roy; A Molyneux
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-29       Impact factor: 3.825

Review 6.  Cerebral aneurysm perforations complicating therapy with Guglielmi detachable coils: a meta-analysis.

Authors:  Harry J Cloft; David F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

7.  Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study.

Authors:  M Bendszus; M Koltzenburg; R Burger; M Warmuth-Metz; E Hofmann; L Solymosi
Journal:  Lancet       Date:  1999-11-06       Impact factor: 79.321

8.  Prevalence and risk of rupture of intracranial aneurysms: a systematic review.

Authors:  G J Rinkel; M Djibuti; A Algra; J van Gijn
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

9.  Clinical and angiographic results of coiling of 196 very small (< or = 3 mm) intracranial aneurysms.

Authors:  W J van Rooij; G J Keeren; J P P Peluso; M Sluzewski
Journal:  AJNR Am J Neuroradiol       Date:  2009-01-08       Impact factor: 3.825

10.  HydroCoil Endovascular Aneurysm Occlusion and Packing Study (HELPS trial): procedural safety and operator-assessed efficacy results.

Authors:  P M White; S C Lewis; H Nahser; R J Sellar; T Goddard; A Gholkar
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-09       Impact factor: 3.825

View more
  4 in total

1.  Endovascular treatment of unruptured A1 segment aneurysms.

Authors:  Huo Xiaochuan; Sun Xiaoyun; Li Youxiang; Guan Ning; Guo Wenshi; Luo Junsheng
Journal:  Interv Neuroradiol       Date:  2013-05-21       Impact factor: 1.610

2.  Intraoperative indocyanine green video angiography (ICG-VA) with FLOW 800 software in complex intracranial aneurysm surgery.

Authors:  Tao Xue; Ruming Deng; Bixi Gao; Zilan Wang; Chao Ma; Wanchun You; Yun Zhu; Zhouqing Chen; Zhong Wang
Journal:  Chin Neurosurg J       Date:  2021-06-01

3.  Predictor and Prognosis of Procedural Rupture during Coil Embolization for Unruptured Intracranial Aneurysm.

Authors:  Kyung Min Lee; Kyung Il Jo; Pyoung Jeon; Keon Ha Kim; Jong-Soo Kim; Seung-Chyul Hong
Journal:  J Korean Neurosurg Soc       Date:  2016-01-20

4.  Detection of impending perfusion deficits by intraoperative computed tomography (iCT) in aneurysm surgery of the anterior circulation.

Authors:  Jun Thorsteinsdottir; Torleif Sandner; Annamaria Biczok; Robert Forbrig; Sebastian Siller; Patricia Bernasconi; Andrea Szelényi; Thomas Liebig; Jörg-Christian Tonn; Christian Schichor
Journal:  Acta Neurochir (Wien)       Date:  2021-10-13       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.